Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans reduced its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 54.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,941 shares of the biotechnology company's stock after selling 42,532 shares during the quarter. Thrivent Financial for Lutherans owned about 0.06% of Ascendis Pharma A/S worth $4,948,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Legato Capital Management LLC raised its stake in shares of Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock worth $264,000 after purchasing an additional 134 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Ascendis Pharma A/S in the third quarter worth $30,000. GAMMA Investing LLC lifted its stake in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after buying an additional 214 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 328 shares during the period.

Remove Ads

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ASND. JPMorgan Chase & Co. upped their target price on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. Cantor Fitzgerald increased their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. UBS Group assumed coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price objective on the stock. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Finally, Evercore ISI raised their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research report on Tuesday, February 18th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $204.64.

Ascendis Pharma A/S Trading Down 4.1 %

Shares of NASDAQ ASND traded down $6.95 during mid-day trading on Tuesday, reaching $161.04. The company had a trading volume of 402,861 shares, compared to its average volume of 459,601. The stock has a market cap of $9.77 billion, a price-to-earnings ratio of -22.68 and a beta of 0.62. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $169.37. The business's 50-day moving average is $142.05 and its 200-day moving average is $136.15.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.